Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles

Journal of Clinical Investigation

Volumn 100, Issue 2, 1997, Pages 464-474

  Castellani, Lawrence W ^a,b   Navab, Mohamad ^a   Van Lenten, Brian J ^a   Hedrick, Catherine C ^a   Hama, Susan Y ^a   Goto, Aimie M ^a   Fogelman, Alan M ^a   Lusis, Aldons J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Chemotaxis; Cholesterol; Lipid peroxidation; Monocytes

Indexed keywords

APOLIPOPROTEIN A2; HIGH DENSITY LIPOPROTEIN; LIPID HYDROPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; GENE OVEREXPRESSION; INFLAMMATION; LIPID ANALYSIS; LIPID COMPOSITION; LIPID PEROXIDATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 0030851389     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119554     Document Type: Article

References (50)

1. Miller, N.E. 1987. Associations of high density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am. Heart J. 113:589-597.
2. Tall, A.R. 1990. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J. Clin. Invest. 86:379-384.
3. Fielding, C.J., and P.E. Fielding. 1995. Molecular physiology of reverse cholesterol transport. J. Lipid Res. 36:211-228.
4. Parthasarathy, S.D., D. Steinberg, and J.L. Witztum. 1992. The role of oxidized low-density lipoproteins in the pathogenesis of atherosclerosis. Annu. Rev. Med. 43:219-225.
5. Berliner, J.A., M. Navab, A.M. Fogelman, J.S. Frank, L.L. Demer, P.A. Edwards, A.D. Watson, and A.J. Lusis. 1995. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation. 91:2488-2496.
6. Parthasarathy, S., and N. Santanam. 1994. Mechanisms of oxidation, anti-oxidants and atherosclerosis. Curr. Opin. Lipidol. 5:371-375.
7. Parthasarathy, S., J. Barnett, and L.G. Fong. 1990. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim. Biophys. Acta. 1044:275-283.
8. Rader, D.J., K. Ikewaki, N. Duverger, I. Feuerstein, L. Zech, W. Connor, and H.B. Brewer, Jr. 1993. Very low high-density lipoproteins without coronary atherosclerosis. Lancet. 342:1455-1458.
9. Karathanasis, S.K. 1992. High density lipoprotein. In Molecular Genetics of Coronary Artery Disease. A.J. Lusis, J.I. Rotter, and R.S. Sparkes, editors. Karger, Basel, Switzerland. 140-171.
10. Warden, C.H., C.C. Hedrick, J.-H. Qiao, L.W. Castellani, and A.J. Lusis. 1993. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science (Wash. DC). 261:469-472.
11. Walsh, A., Y. Ito, and J.L. Breslow. 1989. High levels of human apolipoprotein A-I in transgenic mice result in increased plasma levels of small high density lipoprotein (HDL) particles comparable to human HDL3. J. Biol. Chem. 264:6488-6494.
12. Navab, M., S.S. Imes, S.Y. Hama, G.P. Hough, L.A. Ross, R.W. Bork, A.J. Valente, J.A. Berliner, D.C. Drinkwater, H. Laks, and A.M. Fogelman. 1991. Monocyte transmigration induced by modification of low density lipoprotein in coculture of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J. Clin. Invest. 88:2039-2046.
13. Fogelman, A.M., F. Elahi, K. Sykes, B.J. Van Lenten, M.C. Territo, and J.A. Berliner. 1988. Modification of the Recalde method for the isolation of human monocytes. J. Lipid Res. 29:1243-1247.
14. Gan, K.N., A. Smolen, H.W. Eckerson, and B.N. LaDu. 1991. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab. Dispos. 19:100-106.
15. Stafforini, D.M., T.M. McIntyre, and S.M. Prescott. 1990. Platelet-activatine factor acetylhydrolase from human plasma. Methods Enzymol. 187:344-357.
16. Auerbach, B.J., J.S. Keily, and J.A. Cornicelli. 1992. A spectrophotometric microtiter-based assay for the detection of hydroperoxy derivatives of linoleic acid. Anal. Biochem. 201:375-380.
17. Bernard, D.W., A. Rodriguez, G.H. Rothblat, and J.M. Glick. 1990. Influence of high density lipoprotein on esterified cholesterol stores in macrophages and hepatoma cells. Arteriosclerosis. 10:135-144.
18. Rubin, E.M., R.M. Krauss, E.A. Spangler, J.G. Verstuyft, and S.M. Clift. 1991. Inhibition of early atherogensis in transgenic mice by human apolipoprotein AI. Nature (Lond.). 353:265-267.
19. Qiao, J.-H., P.-Z. Xie, M.C. Fishbein, J. Kreuzer, T.A. Drake, L.L. Demer, and A.J. Lusis. 1994. Pathology of atheromatous lesions in inbred and genetically engineered mice. Arterioscler. Thromb. Vasc. Biol. 14:1480-1497.
20. Schultz, J.R., J.G. Verstuyft, E.L. Gong, A.V. Nichols, and E.M. Rubin. 1993. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature (Lond.). 365:762-764.
21. Kawano, M., T. Miida, C.J. Fielding, and P.E. Fielding. 1993. Quantitation of pre beta-HDL-dependent and nonspecific components of the total efflux of cellular cholesterol and phospholipid. Biochemistry. 32:5025-5028.
22. Navab, M., G.P. Hough, L.W. Stevenson, D.C. Drinkwater, H. Laks, and A.M. Fogelman. 1988. Monocyte migration into the subendothelial space of a coculture of adult human aortic endothelial and smooth muscle cells. J. Clin. Invest. 82:1853-1863.
23. Watson, A.D., M. Navab, S.Y. Hama, A. Sevanian, S.M. Prescott, D.M. Stafforini, T.M. McIntyre, B.N. Du, A.M. Fogelman, and J.A. Berliner. 1995. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J. Clin. Invest. 95:774-782
24. Watson, A.D., M. Navab, G.P. Hough, S.Y. Hama, B.N. La Du, L. Young, H. Laks, L.C. Permut, A.M. Fogelman, and J.A. Berliner. 1994. Biologically active phospholipids in MM-LDL are transferred to HDL and are hydrolyzed by HDL-associated esterases. Circulation. 90:I353.
25. Mackness, M.I., S. Arrol, and P.N. Durrington. 1991. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS. Lett. 286:152-154.
26. Lorentz, K., B. Flatter, and E. Augustine. 1979. Arylesterase in serum: elaboration and clinical application of a fixed-incubation method. Clin. Chem. 25:1714-1720.
27. Stafforini, D.M., G.A. Zimmerman, T.M. McIntyre, and S.M. Prescott. 1992. The platelet-activating factor acetylhydrolase from human plasma prevents oxidative modification of low-density lipoprotein. Trans. Assoc. Am. Physicians. 106:44-63.
28. Mackness, M.I., S. Arrol, C. Abbott, and P.N. Durrington. 1993. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 104:129-135.
29. Blatter, M.-C., R.W. James, S. Messmer, F. Barja, and D. Pometta. 1993. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur. J. Biochem. 211:871-879.
30. Watson, A.D., J.A. Berliner, S.Y. Hama, B.N. La Du, K.F. Faull, A.M. Fogelman, and M. Navab. 1995. Protective effect of HDL associated paraoxonase-inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96:2882-2891.
31. Pieters, M.N., G.R. Castro, D. Schouten, P. Duchateau, J.C. Fruchart, and T.J. Van Berkel. 1993. Cholesterol esters selectively delivered in vivo by high-density-lipoprotein subclass LpA-I to rat liver are processed faster into bile acids than are LpA-I/A-II-derived cholesterol esters. Biochem. J. 292:819-823.
32. Ohta, T., R. Nakamura, Y. Ikeda, M. Shinohara, A. Miyazaki, S. Horiuchi, and I. Matsuda. 1992. Differential effect of subspecies of lipoprotein containing apolipoprotein A-I on cholesterol efflux from cholesterol-loaded macrophages: functional correlation with lecithin: cholesterol acyltransferase. Biochim. Biophys. Acta. 1165:119-128.
33. von Hodenburg, E., S. Hdinen, K.E. Howell, C. Luley, W. Kubler, and H.M. Bond. 1991. Cholesterol efflux from macrophages mediated by high-density lipoprotein subfractions, which differ principally in apolipoprotein A-I and apolipoprotein A-II ratios. Biochim. Biophys. Acta. 1086:173-184.
34. Oikawa, S., A.J. Mendez, J.F. Oram, E.L. Bierman, and M.C. Cheung. 1993. Effects of high-density lipoprotein particles containing apo A-I, with or without apo A-II, on intracellular cholesterol efflux. Biochim. Biophys. Acta. 1165:327-334.
35. Johnson, W.J., E.P. Kilsdonk, A. van Tol, M.C. Phillips, and G.H. Rothblat. 1991. Cholesterol efflux from cells to immunopurified subfractions of human high density lipoprotein: LpA-I and LpA-I:A-II. J. Lipid Res. 32:1993-2000.
36. Barbaras, R., P. Puchois, J.C. Fruchart, and G. Ailhaud. 1987. Cholesterol efflux from cultured adipose cells is mediated by LpAI particles but not by LpAI:AII particles. Biochem. Biophys. Res. Commun. 142:63-69.
37. Eggesbo, J.B., I. Hjermann, P.K. Lund, G.B. Joo, R. Ovstebo, and P. Kierulf. 1994. LPW-induced release of IL-8, TNF-alpha and sCD14 in whole blood and PBMC from persons with high or low levels of HDL-lipoprotein. Cytokine. 6:521-529.
38. Wurfel, M.M., S.T. Kunitake, H. Lichenstein, K.P. Kane, and S.D. Wright. 1994. Lipopolysaccharide (LPS) -binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J. Exp. Med. 180:1025-1035.
39. Flegel, W.A., M.W. Baumstark, C. Weinstock, A. Berg, and H. Northoff. 1993. Prevention of endotoxin induced monokine release by human low-and high-density lipoproteins and by apolipoprotein A-I. Infect. Immun. 61:5140-5146.
40. Baumberger, C., D.R.J. Ulevitch, and J.M. Dayer. 1991. Modulation of endotoxic activity of lipopolysaccharide by high-density lipoprotein. Pathobiology. 59:378-383.
41. Vosbeck, K., P. Tobias, H. Muller, R.A. Allen, K.E. Arfors, R.J. Ulevitch, and L.A. Sklar. 1990. Priming of polymorphonuclear granulocytes by lipopolysaccharides and its complexes with lipopolysaccharide binding protein and high density lipoprotein. J. Leukocyte Biol. 47:97-104.
42. Shih, D.M., L. Gu, S. Hama, Y. Xia, M. Navab, A.M. Fogelman, and A.J. Lusis. 1996. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J. Clin. Invest. 97:1630-1639.
43. Mackness, M.I., D. Harty, D. Bhatnagar, P.H. Winocour, S. Arrol, M. Ishola, and P.N. Durrington. 1991. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis. 86:193-199.
44. Pavkovic, E., V. Simeon, E. Reiner, M. Sucic, and V. Lipovac. 1993. Serum paraoxonase and cholinesterase activities in individuals with lipid and glucose metabolism disorders. Chem. Biol. Interact. 87:179-182.
45. Hegele, R.A., J.H. Brunt, and P.W. Connelly. 1995. Multiple genetic determinants of variation of plasma lipoproteins in Alberta Hutterites. Arterioscler. Thromb. Vasc. Biol. 15:861-871.
46. McElveen, J., M.I. Mackness, C.M. Colley, T. Peard, S. Warner, and C.H. Walker. 1986. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin. Chem. 32:671-673.
47. Bowry, V.W., K.K. Stanley, and R. Stocker. 1993. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc. Natl. Acad. Sci. USA. 89:10316-10320.
48. Saha, N., A.C. Roy, S.H. Teo, J.S.H. Tay, and S.S. Ratnam. 1991. Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins. Clin. Genet. 40:277-282.
49. Blatter Garin, M.C., C. Abbott, S. Messmer, M. Mackness, P. Durrington, D. Pometta, and R.W. James. 1994. Quantitation of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem. J. 304:549-554.
50. Hegele, R.A., J.H. Brunt, and P.W. Connelly. 1995. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler. Thromb. Vasc. Biol. 15:89-95.